Cost-Effectiveness of Meningococcal Vaccination among Men Who Have Sex with Men in New York City

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 2, 2016, Pages 146-154

  Simon, Matthew S ^a   Weiss, Don ^b   Geevarughese, Anita ^b   Kratz, Molly M ^b   Cutler, Blayne ^b,c   Gulick, Roy M ^a   Zucker, Jane R ^b,d   Varma, Jay K ^b   Schackman, Bruce R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c and Children Program   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

cost effectiveness; invasive meningococcal disease; men who have sex with men; meningococcal vaccination; Neisseria meningitidis

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DRUG COST; EPILEPSY; HEARING IMPAIRMENT; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MENINGOCOCCOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED STATES; VACCINATION; ADULT; AGED; COMPLICATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE OUTBREAKS; ECONOMICS; HIV INFECTIONS; IMMUNOLOGY; MALE HOMOSEXUALITY; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; MORTALITY; NEISSERIA MENINGITIDIS; NEW YORK; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE OUTBREAKS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; MODELS, ECONOMIC; NEISSERIA MENINGITIDIS; NEW YORK CITY; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84955629494     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000822     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men-New York City, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013;61:1048.
2. Simon MS, Weiss D, Gulick RM. Invasive meningococcal disease in men who have sex with men. Ann Intern Med. 2013;159:300-301.
3. New York City Department of Health and Mental Hygiene. Alert #5: Invasive Meningococcal Disease in Men Who Have Sex with Men, Four New Cases Reported in 2013, Expanded Vaccine Recommendations. 2013. Available at: http://www.nyc.gov/html/doh/downloads/pdf/cd/2013/13md05.pdf. Accessed April 26, 2013.
4. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1-28.
5. Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:451-455.
6. Lujan-Zilbermann J, Warshaw MG, Williams PL, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012;161:676-681.e672.
7. Miller L, Arakaki L, Ramautar A, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014; 160:30-37.
8. Stephens DS, Hajjeh RA, Baughman WS, et al. Sporadic meningococcal disease in adults: results of a 5-year population-based study. Ann Intern Med. 1995;123:937-940.
9. Cohen C, Singh E, Wu HM, et al. Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS. 2010;24:1351-1360.
10. Los Angeles County Department of Public Health. Public Health Issues New Vaccination Recommendations for Men Who Have Sex with Men (MSM) At-risk for Invasive Meningococcal Disease. 2014. Available at: http://publichealth.lacounty.gov/docs/PressReleaseIMDRecommend-4-2-14.pdf. Accessed April 8, 2014.
11. Chicago Department of Public Health. Invasive Meningococcal Disease in Men Who Have Sex with Men HAN#3. 2015. Available at: https://www.chicagohan.org/mening;jsessionid=26A202153B93BCF32DCEBE 782223277B. Accessed June 26, 2015.
12. Aubert L, Taha M, Boo N, et al. Serogroup C invasive meningococcal disease among men who have sex with men and in gay-oriented social venues in the Paris region: July 2013 to December 2014. Euro Surveill. 2015;20.
13. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Invasive Meningococcal Disease Among Men Who Have Sex with Men. 2013. Available at: http://www.ecdc.europa.eu/en/publications/Publications/rapid-risk-assessment-invasive-meningococcal-disease-among-MSM.pdf Accessed April 8, 2014.
14. Schmink S, Watson JT, Coulson GB, et al. Molecular epidemiology of Neisseria meningitidis isolates from an outbreak of meningococcal disease among men who have sex with men, Chicago, Illinois, 2003. J Clin Microbiol. 2007;45:3768-3770.
15. Tsang RS, Kiefer L, Law DK, et al. Outbreak of serogroup C meningococcal disease caused by a variant of Neisseria meningitidis serotype 2a ET-15 in a community of men who have sex with men. J Clin Microbiol. 2003;41:4411-4414.
16. Weiss D, Varma JK. Control of recent community-based outbreaks of invasive meningococcal disease in men who have sex with men in Europe and the United States. Euro Surveill. 2013;18.
17. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276: 1253-1258.
18. New York City Department of Health and Mental Hygiene. New York City Community Health Survey. Available at: http://www.nyc.gov/html/doh/html/data/survey.shtml. Accessed June 11, 2014.
19. New York City Department of Health and Mental Hygiene. HIV Epidemiology and Field Services Program. Available at: http://www. nyc.gov/html/doh/html/data/hiv-eq.shtml. Accessed June 11, 2014.
20. Bertolini DV, Costa LS, van der Heijden IM, et al. Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults. Vaccine. 2012;30:5482-5486.
21. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol. 2005;162:89-100.
22. Fine P, Eames K, Heymann DL. " Herd immunity ": a rough guide. Clin Infect Dis. 2011;52:911-916.
23. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993; 15:265-302.
24. Davis KL, Misurski D, Miller J, et al. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin. 2011;7:458-465.
25. Erickson LJ, De Wals P, McMahon J, et al. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33:737-739.
26. Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:317-328.
27. Sullivan PW, Ghushchyan V Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26: 410-420.
28. Schackman BR, Goldie SJ, Freedberg KA, et al. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002;22: 27-38.
29. Smith KJ, Wateska AR, Nowalk MP, et al. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307:804-812.
30. Jia H, Zack MM, Thompson WW. The effects of diabetes, hypertension, asthma, heart disease, and stroke on quality-adjusted life expectancy. Value Health. 2013;16:140-147.
31. Barshes NR, Belkin M, Collaborators MS. A framework for the evaluation of "value" and cost-effectiveness in the management of critical limb ischemia. J Am Coll Surg. 2011;213:552-566.e555.
32. National Vital Statistics System Homepage. Available at: http://www. cdc.gov/nchs/nvss.htm. Accessed February 5, 2013.
33. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53:124-130.
34. Mohr PE, Feldman JJ, Dunbar JL. The societal costs of severe to profound hearing loss in the United States. Policy Anal Brief H Ser. 2000;2:1-4.
35. MacKenzie EJ, Jones AS, Bosse MJ, et al. Health-care costs associated with amputation or reconstruction of a limb-threatening injury. J Bone Joint Surg Am. 2007;89:1685-1692.
36. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
37. American Medical Association. CPT Code/Relative Value Search. Available at: https://ocm.ama-assn.org. Accessed April 4, 2013.
38. Gold MR, Siegel JE, Russel LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
39. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349-356.
40. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50, 000-per-QALY threshold. N EnglJ Med. 2014;371:796-797.
41. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50, 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165-178.
42. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br Med J. 2003;326:365-366.
43. Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine. 2009;27:1735-1740.
44. Hartocollis A. For Gay Men, a Fear that Feels Familiar. 2013. Available at: http://www.nytimes.com/2013/05/19/health/for-gay-men-a-fear-that-feels-familiar.html?-r=0. Accessed April 8, 2014.
45. New York City Department of Health and Mental Hygiene. Alert #28: Update: Invasive Meningococcal Disease in Men Who Have Sex with Men. September 5th, 2014. 2014. Available at: https://a816-health29ssl. nyc.gov/sites/NYCHAN/Lists/AlertUpdateAdvisoryDocuments/HAN% 20IMD%20in%20MSM-2014.pdf. Accessed October 12, 2014.
46. Marcus U, Vogel U, Schubert A, et al. A cluster of invasive meningococcal disease in young men who have sex with men in Berlin, October 2012 to May 2013. Euro Surveill. 2013;18.
47. Senate Administration for Health and Social Affairs of the City of Berlin. Recommendation of the Berlin Vaccination Council for Vaccination against Meningococcal Disease 2013. Available at: http://www.berlin. de/sen/gessoz/presse/archiv/20130718.1630.387129.html. Accessed April 9, 2014.
48. Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46:1-13.
49. Keeling MJ, Rohani P. Modeling Infectious Diseases in Humans and Animals. 1st ed. Princeton, NJ: Princeton University Press; 2008.